Draft:Andrew Allen

Apr 23, 2026 - 19:49
0 0
Draft:Andrew Allen

Career: clean up, typo(s) fixed: Chief Executive Officer → chief executive officer

← Previous revision Revision as of 14:18, 23 April 2026
Line 16: Line 16:
In 2009, Allen co-founded [[Clovis Oncology]], where he served as Chief Medical Officer until 2015. During his tenure, the company developed [[Rucaparib]], a PARP inhibitor later approved for ovarian and prostate cancers.{{cite web |title=FDA approves rucaparib for ovarian cancer |url=https://www.fda.gov/drugs/resources-information-approved-drugs/rucaparib |website=U.S. Food and Drug Administration}}{{cite journal |year=2016 |title=Rucaparib monotherapy in patients with BRCA-mutated ovarian cancer |journal=Lancet Oncology |doi=10.1016/S1470-2045(16)30559-9 |pmid=27908594}}
In 2009, Allen co-founded [[Clovis Oncology]], where he served as Chief Medical Officer until 2015. During his tenure, the company developed [[Rucaparib]], a PARP inhibitor later approved for ovarian and prostate cancers.{{cite web |title=FDA approves rucaparib for ovarian cancer |url=https://www.fda.gov/drugs/resources-information-approved-drugs/rucaparib |website=U.S. Food and Drug Administration}}{{cite journal |year=2016 |title=Rucaparib monotherapy in patients with BRCA-mutated ovarian cancer |journal=Lancet Oncology |doi=10.1016/S1470-2045(16)30559-9 |pmid=27908594}}


In 2015, Allen co-founded [[Gritstone bio]] and served as Chief Executive Officer, which developed neoantigen vaccines.
In 2015, Allen co-founded [[Gritstone bio]] and served as chief executive officer, which developed neoantigen vaccines.


Allen has also served on the boards of multiple biotechnology companies.
Allen has also served on the boards of multiple biotechnology companies.
Read More